DRQ is thus our prime candidate for treatment of progressive MS as well other MIF/CD74-dependent inflammatory conditions, including stroke, methamphetamine abuse, traumatic brain injury, Alzheimer’s disease and GBM without the need for histocompatibility testing of DRQ recipients [173]. This evidence concerns the gene CD74 and myeloid sarcoma.